{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:38:56Z","timestamp":1793777936654,"version":"4.6.1"},"reference-count":52,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T00:00:00Z","timestamp":1540512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To investigate the safety and efficacy of\n                      <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\n                      \u2010122, a tumor necrosis factor (\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      )\u2013 and interleukin\u201017A (\n                      <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\n                      \u201017A)\u2013targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients (n = 240) were randomized to receive\n                      <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\n                      \u2010122 (120 or 240 mg every week), adalimumab (40 mg every other week), or placebo in a 12\u2010week double\u2010blind, parallel\u2010group study. The primary efficacy end point was the proportion of patients achieving \u226520% improvement in disease activity according to the American College of Rheumatology response criteria (\n                      <jats:styled-content style=\"fixed-case\">ACR<\/jats:styled-content>\n                      20) at week 12. Secondary and exploratory 12\u2010week end points included 50% improvement (\n                      <jats:styled-content style=\"fixed-case\">ACR<\/jats:styled-content>\n                      50) and 70% improvement (\n                      <jats:styled-content style=\"fixed-case\">ACR<\/jats:styled-content>\n                      70) response rates, and proportion of patients meeting the Psoriasis Area and Severity Index (\n                      <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\n                      ) response criteria for \u226575% (\n                      <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\n                      75) and \u226590% (\n                      <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\n                      90) improvement in skin scores among those with \u22653% of their body surface area affected by psoriasis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In both\n                      <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\n                      \u2010122 dose groups,\n                      <jats:styled-content style=\"fixed-case\">ACR<\/jats:styled-content>\n                      20 response rates at week 12 (64.8\u201375.3%) were superior to that in patients receiving placebo (25.0%) (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) but similar to that in patients receiving adalimumab (68.1%).\n                      <jats:styled-content style=\"fixed-case\">ACR<\/jats:styled-content>\n                      50 and\n                      <jats:styled-content style=\"fixed-case\">ACR<\/jats:styled-content>\n                      70 response rates were also superior in both\n                      <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\n                      \u2010122 dose groups (36.6\u201353.4% and 22.5\u201331.5%, respectively) compared to the placebo group (12.5% and 4.2%, respectively) (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Among eligible patients in the placebo, adalimumab,\n                      <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\n                      \u2010122 120 mg every week, and\n                      <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\n                      \u2010122 240 mg every week treatment groups,\n                      <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\n                      75 responses were achieved in 27.3%, 57.6%, 74.4%, and 77.6% of patients, respectively, whereas\n                      <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\n                      90 responses were achieved in 18.2%, 45.5%, 48.8%, and 46.9% of patients, respectively. Frequencies of treatment\u2010emergent adverse events, including infections, were similar across all treatment groups, causing no discontinuations. No serious infections or systemic hypersensitivity reactions were reported with\n                      <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\n                      \u2010122.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Dual neutralization of\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      and\n                      <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\n                      \u201017A with\n                      <jats:styled-content style=\"fixed-case\">ABT<\/jats:styled-content>\n                      \u2010122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12\u2010week treatment course in patients with PsA.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.40579","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T02:39:17Z","timestamp":1527820757000},"page":"1778-1789","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Phase\n                    <scp>II<\/scp>\n                    Study of\n                    <scp>ABT<\/scp>\n                    \u2010122, a Tumor Necrosis Factor\u2013 and Interleukin\u201017A\u2013Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate"],"prefix":"10.1002","volume":"70","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[{"name":"Swedish Medical Center and University of Washington Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-4503","authenticated-orcid":false,"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Peloso","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Othman","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Li","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki T.","family":"Mansikka","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khatri","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Wishart","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1833"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.4.298"},{"key":"e_1_2_8_4_1","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin C","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_8_5_1","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor\u2010\u03b1 and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch G","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23655"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27622"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-011-1036-6"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000147"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38376"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3431"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12626"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2534-x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024463"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152223"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20221"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22070"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055111"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30194"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/annrheumdis-2014-eular.4676","article-title":"FRI0303 discovery and characterization of ABT\u2010122, an anti\u2010TNF\/IL\u201017 DVD\u2010IG molecule as a potential therapeutic candidate for rheumatoid arthritis [abstract]","volume":"7","author":"Hsieh CM","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.1541"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.01.002"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0580-y"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40319"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40580"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key173"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_8_40_1","first-page":"946","article-title":"A modification of the Health Assessment Questionnaire for the spondyloarthropathies","volume":"17","author":"Daltroy LH","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"e_1_2_8_42_1","first-page":"1401","article-title":"Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v. 2.0","volume":"34","author":"Woodworth T","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1068"},{"key":"e_1_2_8_44_1","volume-title":"Taltz (ixekizumab) prescribing information","year":"2016"},{"key":"e_1_2_8_45_1","volume-title":"Cosentyx (secukinumab) prescribing information","year":"2016"},{"issue":"10","key":"e_1_2_8_46_1","article-title":"Genomic and epigenetic bioinformatics demonstrate dual TNF\u2010\u03b1 and IL17a target engagement by ABT\u2010122, and suggest mainly TNF\u2010\u03b1\u2013mediated relative target contribution to drug response in MTX\u2010IR rheumatoid arthritis patients [abstract]","volume":"68","author":"Georgantas RW","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201601"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141271"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701213"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.65"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40579","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:30:19Z","timestamp":1759923019000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,26]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1002\/art.40579"],"URL":"https:\/\/doi.org\/10.1002\/art.40579","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,26]]},"assertion":[{"value":"2017-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}